Avalo Therapeutics (NASDAQ:AVTX) Given Outperform Rating at Wedbush

Avalo Therapeutics (NASDAQ:AVTX)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report issued on Thursday,RTT News reports. They presently have a $18.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 123.21% from the company’s current price.

Several other equities research analysts have also weighed in on AVTX. Piper Sandler assumed coverage on Avalo Therapeutics in a research report on Friday, February 28th. They set an “overweight” rating and a $48.00 target price on the stock. BTIG Research assumed coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.33.

Avalo Therapeutics Stock Up 0.9 %

Avalo Therapeutics stock traded up $0.07 during midday trading on Thursday, reaching $8.06. The company’s stock had a trading volume of 17,080 shares, compared to its average volume of 76,721. The business has a 50-day simple moving average of $7.42 and a 200-day simple moving average of $9.11. Avalo Therapeutics has a fifty-two week low of $4.43 and a fifty-two week high of $34.46.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after acquiring an additional 3,754 shares during the period. Marshall Wace LLP purchased a new stake in Avalo Therapeutics in the 4th quarter valued at $114,000. Walleye Capital LLC acquired a new stake in Avalo Therapeutics during the 4th quarter worth $145,000. Northern Trust Corp purchased a new position in Avalo Therapeutics during the 4th quarter worth $168,000. Finally, Bank of Montreal Can purchased a new position in Avalo Therapeutics during the 4th quarter worth $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.